Division of Immunology and Allergy, Department of Pediatrics, University of Health Sciences/Dr Sami Ulus Maternity and Children Research and Training Hospital, Ankara, Turkey.
Int Arch Allergy Immunol. 2023;184(8):776-782. doi: 10.1159/000530125. Epub 2023 Apr 18.
The management of the COVID-19 vaccine in children with mastocytosis is unclear due to a lack of data. In the current study, we aimed to evaluate the adverse reactions following COVID-19 vaccination in adolescents with cutaneous mastocytosis (CM).
This study included 27 paediatric patients who were diagnosed with CM and were followed up in the paediatric allergy department of a tertiary care children's hospital.
The median (IQR) age of the patients at the time of COVID-19 vaccination was 180 (156-203) months. Forty-four per cent of patients were vaccinated with the COVID-19 vaccine. Among all participants, the vaccination rate was found to be higher in older children, those who had been diagnosed with MPCM, and those who had not been infected with COVID-19 (p = 0.019, p = 0.009, p = 0.002, respectively). A total of 23 doses of the COVID-19 vaccine, including two doses of Sinovac/CoronaVac and 21 doses of Pfizer/BioNTech, were administered to 12 paediatric patients with CM. One of the patients had a history of intense itch, erythematous urticarial plaques, and had an exacerbation of existing skin lesions within 24-48 h after both doses of Pfizer/BioNTech vaccination.
The COVID-19 vaccination of patients with CM in this series seems to be safe, and the rate of adverse events was comparable to that in the general population. These results found in adolescents with CM are in line with the existing evidence that CM does not preclude vaccination in children.
由于缺乏数据，COVID-19 疫苗在肥大细胞增多症儿童中的管理尚不清楚。在本研究中，我们旨在评估青少年皮肤肥大细胞增多症（CM）患者接种 COVID-19 疫苗后的不良反应。
本研究纳入了 27 名在三级儿童专科医院儿科过敏科就诊的被诊断为 CM 的儿科患者。
COVID-19 疫苗接种时患者的中位数（IQR）年龄为 180（156-203）个月。44%的患者接种了 COVID-19 疫苗。在所有参与者中，年长儿童、已被诊断为 MPCM 的儿童和未感染 COVID-19 的儿童的疫苗接种率更高（p = 0.019、p = 0.009、p = 0.002）。12 名 CM 患儿共接种了 23 剂 COVID-19 疫苗，包括两剂科兴/CoronaVac 和 21 剂辉瑞/BioNTech。一名患者在接种两剂辉瑞/BioNTech 后 24-48 小时内出现剧烈瘙痒、红斑性荨麻疹和现有皮肤病变加重。
本系列 CM 患者接种 COVID-19 疫苗似乎是安全的，不良事件发生率与普通人群相当。这些在 CM 青少年中发现的结果与 CM 不排除儿童疫苗接种的现有证据一致。
